A
Acid-suppressing
agents
Adherence
AIDS
(Acquired Immune Deficiency Syndrome)
AIDS-related
dementia (HIV encephalopathy)
Andropause
Antibodies
Antidepressants
Antigen
Antioxidants
Antiretrovirals
(ARVs)
Asymptomatic
Atherosclerosis
B
Blinded
clinical trial
Blood-brain
barrier
Bone
mineral density (BMD)
C
Cardiovascular
disease
CCR5
co-receptor
CD4
T cell count
Chancre
Cirrhosis
Cohort studies
Complementary
therapy or alternative therapy
Coronary
heart disease
Coronary
or cardiac risk factors
Creatinine
D
Dopamine
Drug
Interaction
E
Electrolyte
Entry inhibitors (fusion inhibitors and CCR5 antagonists)
Expanded
Access
F
Framingham
score
G
Genotype
Genotyping
Glomerular
filtration rate (GFR)
H
HAART
(Highly Active Antiretroviral Therapy)
Hallucinogenic
Heartburn
Hemoglobin
HIV
(Human Immunodeficiency Virus)
HPV
(human papilloma virus)
Hypogonadism
Hypothyroidism
I
Immune
system
Integrase inhibitors
Idiopathic
K
Kaposi's
sarcoma
Kidney
stones
L
Lactic
acidosis
Latent
Lipids
Lipoatrophy
Lipodystrophy
Lymph
nodes
Lymphocytes
Lymphoma
M
Maturation inhibitors
Median
Metabolic
complications
Metabolic
diseases
Metabolism
Modifiable
risk factors
Multiple
Drug Rescue Therapy (MDRT)
Mutation
N
Nadir
CD4 Count
Neurotransmitters
Non-Hodgkin's
lymphoma
NRTIs
(nucleoside reverse transcriptase inhibitors)
NNRTIs
(non-nucleoside reverse transcriptase inhibitors)
O
Opportunistic
infections
Oral
Candidiasis
Osteoporosis
P
Pap
test, or Pap smear
Peripheral
neuropathy
Placebo
Pre-exposure
prophylaxis (PrEP)
Protease
Protease inhibitors
R
Recreational
drugs
Regimen
Replication
Resistance
Resistance
mutations
Retrovirus
Reverse
transcriptase
S
Salvage
therapy
Seroconversion
Serodiscordant
Seronegative
Serotonin
Side
effects
Special
Access Program (SAP)
Superinfection
or re-infection
Steroids
Symptoms
T
T
Cells
Testosterone
Toxic
substances
Tropism
assay
U
Undetectable
viral load
V
Variant
Viral
load
Viral
rebound
Viral
vector
Virologic
failure
Wild-type
virus
